Ji X, Sui L, Song K, et al. - Researchers herein measured and analyzed programmed cell death protein 1 ligand 1(PD-L1) and poly ADP-ribose polymerase-1(PARP1) in neuroendocrine cervical cancer (NECC) and determined the application value of PD-1/PD-L1 and PARP1 inhibitors in NECC. They collected the NECC cases with formalin-fixed paraffin-embedded tissue blocks, and performed immunohistochemical (IHC) staining of PD-L1, PARP1, Mismatch repair proteins (MMRs), and P53. A total of 20 cases were finally included. As per the IHC results of PD-L1, PARP1, and MMRs, NECC was suggested to be the target of immunotargeted therapy. The case verified the effectiveness of immune checkpoint therapy in patients with PD-L1 positive and MMRs loss. Considering the clinical practicability, researchers recommend collecting more cases, and further searching the necessity for effective biomarkers.